A recent clinical study in adults with liver cancer demonstrated that GPC3-directed CAR T cells co-expressing IL-15, but not GPC3 CAR T cells alone, achieved a disease control rate of 66.7% (8 of 12 patients) and an objective response rate of 33.3% (4 of 12 patients) [77]. This evidence concerns the gene GPC3 and liver cancer.